Sugi Predict

Sugi Predict / Compounds / SCHEMBL2917545

SCHEMBL2917545

SCHEMBL2917545

CC1Oc2ccc(N)cc2NC1=O

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 7/20 0.60
▸ PDE3B Q13370 3/20 0.51
▸ PDE3A Q14432 3/20 0.51
▸ SMYD3 Q9H7B4 3/20 0.50
▸ MAOB P27338 1/20 0.43
▸ ADORA2A P29274 1/20 0.43
▸ BRD4 O60885 1/20 0.41
▸ CREBBP Q92793 1/20 0.41
▸ USP2 O75604 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496236 1.00 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3MAOB
SCHEMBL2104033 1.00 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3MAOB
SCHEMBL31481189 0.87 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3MAOB
SCHEMBL10130365 0.81 PARP1 (0.62) PARP1PDE3BPDE3ASMYD3BRD4
SCHEMBL5670717 0.81 PARP1 (0.62) PARP1PDE3BPDE3ASMYD3BRD4
SCHEMBL10130302 0.81 PARP1 (0.62) PARP1PDE3BPDE3ASMYD3BRD4
SCHEMBL6996227 0.80 PARP1 (0.61) PARP1PDE3BPDE3ASMYD3MAOB
SCHEMBL5670852 0.80 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3
SCHEMBL3600753 0.80 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3MAOB
SCHEMBL292432 0.80 PARP1 (0.60) PARP1PDE3BPDE3ASMYD3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
EP-2699572-B1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2016-08-10 — — EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 — — EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 — — US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 — — EP disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 — — US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 — — US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 — — US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 — — EP disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK PARP1 3745/4885PDE3B 1969/4885PDE3A 2256/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK PARP1 2361/4885PDE3B 1251/4885PDE3A 1332/4885
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 PARP1 1468/4885PDE3B 3066/4885PDE3A 2554/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK PARP1 3745/4885PDE3B 1969/4885PDE3A 2256/4885
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K PARP1 1719/4885PDE3B 2286/4885PDE3A 2546/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK PARP1 3745/4885PDE3B 1969/4885PDE3A 2256/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 PARP1 3006/4885PDE3B 2395/4885PDE3A 2593/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PARP1 3557/4885PDE3B 2159/4885PDE3A 2487/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK PARP1 3557/4885PDE3B 2159/4885PDE3A 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.